Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer

Journal of Clinical Oncology

Volumn 13, Issue 12, 1995, Pages 2936-2943

  Moertel, Charles G ^b   Fleming, Thomas R ^b   Macdonald, John S ^b   Haller, Daniel G ^b   Laurie, John A ^b   Tangen, Catherine M ^b   Ungerleider, James S ^b   Emerson, William A ^b   Tormey, Douglass C ^b   Glick, John H ^b   Veeder, Michael H ^b   Mailliard, James A ^b  

^a Southwest Oncology Group   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; LEVAMISOLE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0028835122     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.12.2936     Document Type: Article

References (15)

1. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy ol resected colon carcinoma. N Engl J Med 322:352-358, 1990
2. Cohen AM: Surgical considerations in patients with cancer of the colon and rectum. Semin Oncol 18:381-387, 1991
3. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
4. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 7:1447-1457, 1989
5. SAS Institute Inc: SAS Technical Report P-229, version 6.07 edition. Cary, NC, SAS Institute, 1992, p 433
6. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
7. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
8. Chlebowski RT, Lillington L, Nystrom JS, et al: Late mortality and levamisole adjuvant therapy in colorectal cancer. Br J Cancer 69:1094-1097, 1994
9. Witzig TE, Loprinzi CL, Gonchoroff NJ, et al: DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68:879-888, 1991
10. Jen J, Kim H, Piantadosi S, Liu ZF, et al: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213-221, 1994
11. Moertel CG, Loprinzi CL, Witzig TE, et al: The dilemma of stage B-2 colon cancer. Is adjuvant therapy justified? A Mayo clinic/ North Central Cancer Treatment Group study. Proc Am Soc Clin Oncol 9:108, 1990 (abstr)
12. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Patients With Colon Cancer and Rectum Cancer. Office of Medical Applications of Research. Bethesda, MD, National Institutes of Health, 1990, April 16-18
13. Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
14. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Protocol C-03. J Clin Oncol 11:1879-1887, 1993
15. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177-1183, 1994